Kiora Pharmaceuticals, Inc. reported a net loss of approximately $10.8 million for the fiscal year ending December 31, 2025, a significant decline from a net income of $3.6 million in 2024. The company's total revenue for 2025 was zero, down from $16 million in the previous year, primarily due to the absence of collaboration revenue following the strategic development agreement with Théa Open Innovation (TOI) in January 2024. This agreement had previously contributed to the revenue stream through an upfront payment and milestone achievements. The decrease in revenue reflects the company's ongoing transition as it focuses on advancing its clinical programs, particularly KIO-301 and KIO-104.
Kiora's research and development expenses rose to $10.8 million in 2025, compared to $7.8 million in 2024, driven by increased spending on clinical trials and preclinical activities for KIO-301. The company is currently conducting a Phase 2 clinical trial for KIO-301, which targets patients with retinitis pigmentosa, and has received regulatory approval to initiate this trial. Additionally, Kiora is advancing KIO-104, aimed at treating retinal inflammatory diseases, with a Phase 2 trial also underway. The company reported an impairment charge of $4.6 million related to KIO-104, attributed to a decline in market capitalization rather than adverse changes in clinical progress.
Operationally, Kiora's total assets decreased to $24.3 million as of December 31, 2025, down from $36.5 million in 2024. The decline in assets is largely due to the impairment of in-process research and development and a reduction in cash and short-term investments. The company had cash and cash equivalents of approximately $8.7 million and short-term investments of $8.4 million at year-end, which management believes will be sufficient to fund operations into late 2027. Kiora's total liabilities also decreased to $8.1 million, reflecting a reduction in accrued expenses and contingent consideration.
Looking ahead, Kiora Pharmaceuticals anticipates continued operating losses as it invests in the development of its product candidates. The company plans to seek additional financing through equity offerings, collaborations, and other arrangements to support its ongoing operations and clinical trials. Kiora's management remains focused on advancing its pipeline and achieving regulatory approvals, which are critical for future revenue generation. The company has not yet generated significant revenue from product sales and does not expect to do so until its product candidates receive marketing approval.
About KIORA PHARMACEUTICALS INC
Kiora Pharmaceuticals is a clinical-stage biotech company focused on developing therapies for retinal diseases. Its core assets include KIO-301, a potential vision-restoring small molecule for retinitis pigmentosa, and KIO-104, an anti-inflammatory treatment for retinal conditions. The company advances its products through partnerships, proprietary IP, and clinical trials, targeting underserved ophthalmic markets with innovative, targeted therapies for vision loss and ocular inflammation.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.